HemA

ICER has released a draft report that indicates Roctavian, BioMarin’s new gene therapy for hemophilia A, will beat the current antibody-based therapeutic Hemlibri. Unlike Hemlibri, which is a prophylactic, Roctavian restores the gene lacking in hemophilia A, factor VIII. The organization predicts that the one-time price of $2.5 million for Roctavian will be substantially lower than that of 12 years worth of Hemlibra at $640,000 annually.